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Diagnosis of infectious pericardial disease has been challenging in the developing world despite improvement of 
treatment modalities. The diagnostic utility of pH in diagnosing infectious pericardial fluid is unknown, yet this 
concept is well studied in pleural fluid. This cross-sectional diagnostic study evaluated the diagnostic utility of  
pH in infectious compared to non-infectious pericardial effusions in a high-burden setting. 
Methods: Patients of 18 years with moderate to large effusion between the 1st February 2016 and 31st May2018 
were enrolled at Groote Schuur Hospital in Cape Town, South Africa. After safe pericardiocentesis, pH was 
measured with a blood gas analyzer. Mycobacterium tuberculosis culture and/or gene Xpert for TB and/or bacteria 
culture and/or microscopy served as the reference standard for definite infectious pericardial effusions. We 
calculated sensitivity, specificity, positive and negative predictive values, negative and positive likelihood ratios 
for an a priori pH cut off of 7.35. Receiver operating characteristic curve analysis was used for selection of ideal 
pH cut off. 
RESULTS 
 
Using a set sensitivity of 70% we estimated that we needed to recruit a sample size of 149 subjects for a 95% 
confidence interval and power of 80%. We screened 200 patients, and excluded 60 because they did not meet the 
appropriate exclusion criteria. 
The prevalence of infectious pericarditis was 27.1% (n/N=34/140) as confirmed by the reference standard. We 
found the median pH (IQR) was 7.30(7.20-7.30) for definite infection, 7.30(7.30-7.35) for probable infection and 
7.50(7.40-7.55) for non-infectious effusions p value <0.01 (test for trend). At a cut off of <7.35, the sensitivity 
was 89.5(95% CI: 75%.5-97.1%) and the specificity was 72.5% (95% CI: 62.8%-80.9%). The ideal ROC- 
determined cut off for pH that would give maximum sensitivity and specificity was ≤7.30 and the maximum 
sensitivity and specificity at optimum cut off are 86.8% (95% CI:71.9 - 95.6) and 86.8% (95% CI:71.9 - 95.6), 
respectively. The area under the curve at this cut-off point is 0.86 (95% CI 0.79 to 0.9), p<0. 001. 







In conclusion, pericardial PH offers diagnostic utility for infectious causes of pericardial effusions using both a 
PH of 7.35 and an ideal cut-off of 7.30. We recommend that given the simplicity of the test it should be 
adopted in evaluation of patients with pericardial effusions. 





CHAPTER ONE: INTRODUCTION 
 
1.1 PERICARDIUM AND ITS ROLE IN HEALTH 
 
The pericardium is one of the serosal cavities of mammals.(1) It is a fibrous—serosal conical sac enclosing the 
roots of the aorta and the pulmonary artery. (2) Pericardium isolates the heart from the adjacent tissues, allowing 
its free movement within the boundaries of the pericardial cavity and is filled with a small amount of fluid which 
is called pericardial fluid. (2) 
 
The normal pericardium contributes to important functions of the heart. It is necessary for: (1) lubricating the 
moving surfaces of the heart, (2) stabilizing the heart anatomic position, (3) isolating the heart from the adjacent 
anatomical structures, prohibiting the adhesion formation, the inflammatory or neoplastic extension, (4) limiting 
heart dilatation during diastole, reducing the endomyocardial tension, (5) preventing cardiac hypertrophy in 
pressure overload conditions, (6) reducing the right ventricular impulse work in left ventricular overload 
conditions, (7) the ventriculoarterial blood retrogression prevention during high end- diastolic ventricular 
pressures, (8) the preservation of the negative intrathoracic pressure, which is crucial for blood filling of atria, 
(9) the nervous stimulation response and regulation of the cardiac frequency and arterial blood pressure, (10) the 
formation of a hydrostatic compensation system ensuring that end- diastolic pressure remains the same at all 
hydrostatic levels and the Frank–Starling mechanism is functional. (3) 
 
1.1.1 Global burden of pericardial disease 
  
Pericardial disease remains an important cause of mortality and morbidity in the world. (4) Pericarditis makes up 
about 5% of admissions in accident and emergency units in the developed world. (5) 
 
The etiology of pericardial disease in developed countries has been found to be mainly idiopathic in over 89% of 
patients, with the remainder being due to infections and malignancy (6). A study done in Western Europe 
revealed 5% of the patients to have infectious pericarditis, which is different from Imazio et al’s study in Western 
Europe where 20% of cases were due to infectious pericarditis. (7) Over the years the incidence and prevalence of 
 




pericarditis has been difficult to measure even in developed settings, but subclinical pericarditis has been found in 
1% of autopsies. (8) 
There is a growing burden of pericarditis in Africa and most especially in the sub-Saharan Africa. This is mainly 
due to the huge burden of HIV/AIDS which predisposes patients to TB in various organs/sites including the 
pericardium i.e. TB pericarditis, and other opportunistic infections. (9) In developing countries infectious 
pericardial effusions are more prevalent among patients with pericardial disease than idiopathic causes, as in the 
case of the developed world. A study done by Reuter et al (10) in a large academic hospital in South Africa 
revealed that 71.6% of the effusions were of an infectious cause. In another study done by Pandie et al, 86.1% of 
the patients at another large academic hospital in South Africa had infectious pericarditis.(11) A series of these 
published studies, as described above are in Table 1 highlighting selected papers reflecting the pattern of 
pericardial disease in both developed and developing worlds. 
 
With the high burden of HIV in Sub-Saharan Africa, the number of people presenting with pericardial effusion 
has increased. Of patients presenting with pericardial effusions 67% are HIV positive. (12) 
 
1.2 MORBIDITY AND MORTALITY OF PERICARDIAL DISEASE 
 
Patients admitted with acute pericarditis with advancing age and co-infections are over three times and thirteen 
times more likely to suffer in hospital mortality respectively.(13) In study done by Mpiko et al on Tuberculous 
pericarditis with and without HIV, patients with HIV   had larger pericardial effusions and more cardiovascular 
impairment, contributing to greater morbidity and later mortality among these patients .(14) In older studies the 
overall mortality of patients with non TB purulent pericarditis has been found to be 77% and reduced to 55% in 
those who received appropriate treatment.(15) A five year retrospective study of 57 patients in Zimbabwe 
revealed 100 % mortality among patients with acute purulent pericarditis.(16) Another study showed the 
mortality of purulent pericarditis to be 100% in untreated patients in Ohio.(17) Of patients diagnosed with 





constrictive pericarditis, 60% will die in the next 10 years from date of diagnosis. (18) In a study done by Mayosi 
et al, the overall mortality of patients with TB pericarditis was 18.05%. (19, 20) 
The presumptive diagnosis of TB pericarditis has been identified as an independent risk factor for mortality, 
especially in HIV positive patients, in whom the risk of mortality is approximately 4.5 times higher [HR 5.35, 
95% CI 1.76-16.25] than HIV uninfected controls. (21) Patients with pericarditis in the era of HIV have been 
found to suffer greater morbidity. (22, 23) There is increased mortality from pericarditis among patients with HIV 
due to tamponade and constriction. (20, 24) In a recently published IMPI trial, patients with HIV were found to 
have less constriction from TB pericarditis and thus fewer complications from constriction, compared to HIV 
negative population. (19, 20) 
 
1.2.1 Diagnosis of pericarditis 
 
The diagnosis of pericarditis can be made from a medical history, clinical examination, electrocardiogram and 
echocardiogram, although it is much more complicated establishing its etiology. (6) The clinical diagnosis of 
acute pericarditis is reached when a patient has two of the following: typical chest pain, pericardial rub, wide 
spread ST elevation and pericardial effusion. Elevated inflammatory markers such as C-reactive protein and 
erythrocyte sedimentation rate are confirmatory of a diagnosis of pericarditis. (25) Features associated with high 
risk pericarditis (non-viral or non-idiopathic, recurrence, constriction and cardiac tamponade) include: fever 
>38.0 degrees, sub-acute presentation, immunosuppression, trauma, anti-coagulation, myopericarditis, severe 
pericardial effusion (diastolic echo free fluid more than 20mm) and tamponade. (26) 
 
Therapeutic pericardiocentesis is recommended in patients that have symptomatic large effusions (≥ 2cm on 
echocardiogram in diastole). Pericardial effusions and diagnostic pericardiocentesis is recommended where there 
is a high suspicion of infectious and neoplastic pericardial effusions. (27) Cardiac catheterization and 2-(18F)- 
Fluoro-2-deoxy-D-glucose (FDG) uptake with PET-CT have also become very useful in diagnosis of pericardial 
disease especially in effusive pericarditis and pericardial malignancy respectively. (28, 29) 





Newer point-of-care diagnostic tests have been introduced. Adenosine Deaminase (ADA) has been used in the 
diagnosis of TB pericarditis (TBP). A Meta-analysis showed pooled sensitivity was 0.96 and specificity was 0.96 
(30). Pandie et al showed that unstimulated interferon gamma (uIFNγ) offers superior accuracy for the diagnosis 
of microbiologically confirmed TBP, compared to the new Xpert MTB/RIF test and the established ADA assay. 
(11) Magnetic resonance and CT have been found to be useful in the diagnosis of pericarditis in the presence of 
constriction and a mass. (31, 32) Pericardial biopsy is useful in diagnosing and determining specific etiology, 
especially in patients who are having recurrent pericarditis (33). 
 
 
The diagnosis of infectious pericarditis (including TB) pericarditis is very challenging, and this has great impact 
on mobility and mortality (34). The use of simple and affordable tests may simplify and speed up the diagnosis of 
disease, and thus improve the outcome from disease treatment. In the study done by Pandie et al, over 87% of 
pericardial effusions were infectious and the outcome was worse in the non-infectious group. (11) A simple test, 
such as pH to differentiate infectious from non-infectious pericardial effusion, will then be very useful as it will 
simplify and enable timely and appropriate patient management and thus improve the outcome. 





1.1 MECHANISMS OF PERICARDIAL INJURY AND CONSTRICTION: 
 
Figure 1: The diagram demonstrates the pathophysiological mechanism of pericardial injury and construction.  
It starts with an insult to the pericardium, this is followed by inflammatory infiltration with the release of IF- 
IL-8, TNF- and IL-6. This immune cell recruitment leads increase in TGF- and CTGF with resultant loss of 
mesothelial cell architecture and finally fibrosis which is the hall mark of constriction. 
 
Reproduced with permission from the Editor of World Journal of cardiology 
 
1.3 STUDIES DONE ON PH ON PLEURAL FLUID: LESSONS LEARNT 
 
PH has been used in pleural effusions for diagnostic purposes and therefore such studies will be useful to asses if 
we can adapt the use of pH in diagnosis of pericardial effusions [Table 2]. Pleural pH less than 7.30 has been 
found to correlate with infectious causes of pleural effusions, irrespective of the serum pH. (35). In a meta-analysis 
of chemistry predictors of complicated pleural effusions, pH was found to be the most effective predictor of 
complicated (infected) pleural effusion, [AUC:0. 92, CI: 0. 90-0.94] (36). PH as a diagnostic tool in pleural 
disease has been validated and recommended for use. (37) Pleural fluid studies have been done where pleural pH 
less than 7.20 was used to signify infectious pleural effusion. (38) 
 
 





Pleural fluid pH provides more useful information for estimating the likelihood of pleurodesis failure, for which 
continuous likelihood ratios provide more information than binary or multilevel likelihood ratios.(39) pH less 
than 7.2 has been found to predict infectious pleural effusion, and is thus a guide to management of such 
patients.(40, 41) A study done by Light et al showed pH less than 7.2 to signify infectious pleural effusion and 
demonstrated that patients who were treated successfully with antibiotics showed their pH go above 7.2.(42) 
 
Another study demonstrated that pH less than 7.3 and glucose less than 60mg/dl signify infectious pleural 
effusions. (43) A study by Potts et al also revealed pH less than 7.3 signified infectious pleural effusions. 
(44) 
Ferreiro et al revealed that pH less than 7.2 signifies pleural effusions complicated by infection. (45) In a study by 
 
Fanjul et al an acidic pH less than 7.0 was found not only to be a predictor of pleural effusions complicated by 
infection, but was also a marker of poor outcome, thus prognostic. (46) Table 2 illustrates some of the studies 
described above. 
 
1.3.1 Mechanism of low pH in pleural fluid and other serosa cavities 
 
The pathophysiology of low pH in pleural fluid and other serosa cavities is poorly understood. However, existing 
theories suggest that it is due to an increased production of carbon dioxide (CO2) by leucocytes and microbes 
from glucose metabolism, and by reduced diffusion of CO2, hydrogen ions and glucose across a diseased 
membrane. (47) 
 
1.3.2 Use of pH in pericardial disease 
 
The use of pericardial pH as a guide to diagnosis has not been well validated. Animal studies have had 
contradictory results with the use of pH in pericardial fluid analysis, with some demonstrating a pH lower than 
7.80 in neoplastic pericardial effusion, as opposed to idiopathic pericardial effusions, and others not 
demonstrating a difference in the two categories in dogs (48, 49). However, these studies did not assess the use of 
pH in differentiating between pericardial effusions of infectious and non-infectious etiology. A literature search 
yielded only two such studies. First, a small study of 13 surgical patients has shown that pH less than 7.08 





is associated with infectious pericardial effusions. (50) Second, another small study done on 15 children with 
purulent pericardial effusions revealed an average pH of 7.01± 0.06. However, these children were culture 
negative for both pericardial effusions and blood. (51) A table summarizing these studies is given below (Table 
3). 
 
Due to the behaviour and characteristics of pericardial fluid compared to pleural fluid, Lights’ criteria have not 
been found to show the same applicability in differentiating exudative and transudative effusions.(49) Fluid is 
exudate if one of the following Light’s criteria is present; 
 
a) Effusion protein/serum protein ratio greater than 0.5 
 
b) effusion Lactate dehydrogenase (LDH)/serum LDH > 0.6 
 
c) LDH in effusion > 2/3 of that in serum LDH upper limit 
 
Given all these uncertainties regarding the use of pH in pericardial disease, we carried out a study to assess the 
utility of pH in differentiating infectious and non-infectious causes of pericardial effusions. 
 
1.4 PURPOSE OF THE STUDY 
 
The overall purpose of this study was to improve the diagnosis of infectious pericarditis by introducing a simple 
and rapid method of identifying infectious pericardial effusions during pericardiocentesis. This study aimed to 
determine the diagnostic accuracy of pH estimation in the diagnosis of infectious pericarditis in patients with 
pericardial effusions eligible for pericardiocentesis (effusions of more than 1cm on echocardiogram in diastole) 
presenting to Groote Schuur Hospital. The utility of such a simple test would simplify diagnosis and positively 
impact prognosis. 







We hypothesize that an acidic pH (i.e. less than 7.35) as determined by a blood gas analyser as the index test, can 
accurately differentiate infectious from non-infectious causes of pericardial effusion in patients with moderate to 
large pericardial effusions. 
1.4 OBJECTIVES 
 
1.5.1 Primary objectives 
 
To determine the accuracy of pericardial fluid pH as a test to differentiate infectious versus non-
infectious pericardial effusions 
To determine the ideal pH cut off between infectious and non-infectious pericardial effusion using 
Receiver operating characteristics (ROC) curves. 
 
1.5.2 Secondary objectives 
 
To describe the diagnostic accuracy of pericardial fluid pH determination added to ADA(>35IU) in the 
diagnosis of tuberculous pericarditis 
To determine the Sensitivity, specificity, negative predictive value, positive predictive value, negative, 
positive likelihood ratios and Area under the curve (AUC) using acidic pH cutoff of 7.35 as stated by 
NHLS 
1.6 RESEARCH SETTING METHODS AND DESIGN: 
 
This study was carried out at the Division of Cardiology, Groote Schuur Hospital (GSH) in Cape Town, one of 
two provincial government-funded, adult, academic tertiary health facilities that serves a population of >2 million 
people with a wide socioeconomic ethnic and cultural diversity from Western Cape. It was a cross sectional 
substudy of the IMPI 2-pilot trial, which compared fibrinolytic facilitated pericardiocentesis in patients with 
effusive pericarditis of all aetiologies, with routine pericardiocentesis for the reduction of constrictive pericarditis 
(https://clinicaltrials.gov/ct2/show/NCT02673879). Participants included in the analysis included 





adults with moderate to large pericardial effusions enrolled into IMPI-2 between February 2016 to May 2018. In 
order to enrich the proportion of patients with non-infections pericardial effusions and normal pericardial fluid, 
patients under-going open cardiac surgery were also consented for the during the same period 
 
1.6.1 ETHICAL CONSIDERATIONS: 
 
Ethical approval was thus obtained from the Human Ethics Research Committee, University of Cape Town 
(HREC/REF: 475/2015 and all participants signed informed consent to participate 
1.6.2 AUTHOR GUIDELINES FOR CARDIOVASCULAR JOURNAL OF AFRICA 
 




Abstract (150 words) a short inclusive statement suitable for direct electronic abstracting, identifying the 
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Key words; maximum six key words for indexing. Introduction: concise description of background, sufficient 
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Methods; a brief description of the study design, procedures, analytical techniques and statistical evaluation. 
Results: a clear account of the study findings using quantitative language where possible and cross-referenced 
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Discussion: an interpretation of the study placed within the context of current knowledge, leading to specific 
conclusions where possible. 
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Diagnosis of infectious pericardial disease has been challenging in the developing world despite improvement of 
treatment modalities. The diagnostic utility of pH in diagnosing infectious pericardial fluid is unknown, yet this 
concept is well studied in pleural fluid. This cross-sectional diagnostic study evaluated the diagnostic utility of  
pH in infectious compared to non-infectious pericardial effusions in a high-burden setting. 
Methods: Patients of 18 years with moderate to large effusion between the 1st February 2016 and 31st May2018 
were enrolled at Groote Schuur Hospital in Cape Town, South Africa. After safe pericardiocentesis, pH was 
measured with a blood gas analyzer. Mycobacterium tuberculosis culture and/or gene Xpert for TB and/or bacteria 
culture and/or microscopy served as the reference standard for definite infectious pericardial effusions. We 
calculated sensitivity, specificity, positive and negative predictive values, negative and positive likelihood ratios 
for an a priori pH cut off of 7.35. Receiver operating characteristic curve analysis was used for selection of ideal 
pH cut off. 
RESULTS 
 
Using a set sensitivity of 70% we estimated that we needed to recruit a sample size of 149 subjects for a 95% 
confidence interval and power of 80%. We screened 200 patients, and excluded 60 because they did not meet the 
appropriate exclusion criteria. 
The prevalence of infectious pericarditis was 27.1% (n/N=34/140) as confirmed by the reference standard. We 
found the median pH (IQR) was 7.30(7.20-7.30) for definite infection, 7.30(7.30-7.35) for probable infection and 
7.50(7.40-7.55) for non-infectious effusions p value <0.01 (test for trend). At a cut off of <7.35, the sensitivity 
was 89.5(95% CI: 75%.5-97.1%) and the specificity was 72.5% (95% CI: 62.8%-80.9%). The ideal ROC- 
determined cut off for pH that would give maximum sensitivity and specificity was ≤7.30 and the maximum 
sensitivity and specificity at optimum cut off are 86.8% (95% CI:71.9 - 95.6) and 86.8% (95% CI:71.9 - 95.6), 
respectively. The area under the curve at this cut-off point is 0.86 (95% CI 0.79 to 0.9), p<0. 001. 







In conclusion, pericardial PH offers diagnostic utility for infectious causes of pericardial effusions using both a 
PH of 7.35 and an ideal cut-off of 7.30. We recommend that given this a simple test it should be adopted in 
evaluation of patients with pericardial effusions. 
 
2.1 INTRODUCTION 
Pericarditis is the cause of chest pain in up to approximately 5% of adult patients presenting to the emergency 
room for the evaluation of chest pain. (5) The etiology of pericardial disease in this population is predominantly 
idiopathic (6). In sub-Saharan Africa, there is a growing burden of pericarditis that is due mainly to the huge 
burden of HIV/AIDS which predisposes patients to Tuberculosis (TB) and other opportunistic infections in 
various organs/sites including the pericardium. (9) The etiology of pericardial disease in the developing world and 
much of sub-Saharan Africa is due to infections mainly (70%). (10, 11) 
Pericarditis has been associated with high morbidity and mortality particularly when the etiology is infectious. In 
the context of HIV infection, patients with pericarditis have larger pericardial effusions and more cardiovascular 
impairment due to tamponade and heart failure, than their HIV negative counterparts , contributing to greater 
morbidity and later mortality among these patients in both the developed and developing world.(14, 52) (22, 23) 
Patients with advancing age and co-morbidities admitted with acute pericarditis are over three times more likely 
to suffer in-hospital mortality in the developed world.(13) 
 
Given that the infectious etiology of pericarditis is a major determinant of the outcome, the ability be to recognize 
it rapidly and accurately is of great importance. However, this is very challenging, particularly in the setting of 
HIV, TB and in geographies where modern diagnostic laboratory facilities are scarce because of resources (34). 
The use of microscopy on pericardial fluid for TB is not useful. While, culture is the diagnostic goal standard but 
it is associated with long waiting times of up to 8 weeks. Surrogate biochemical tests for the diagnosis of TB 
pericarditis (TBP) such as adenosine deaminase (ADA) are also available is some clinical and research labs; a 
meta-analysis of the diagnostic utility of ADA showed a pooled sensitivity of 96% and a specificity of 96% (30). 





Pandie et al showed that unstimulated interferon gamma (uIFNγ) offers superior accuracy for the diagnosis of 
microbiologically confirmed TBP, compared to the new Xpert MTB/RIF test and the established ADA assay. (11) 
However, many of these tests are not widely available at the rural and peri-urban clinics and community health 
care centers throughout sub Saharan Africa where patients present. 
Given these significant limitations of currently available tests, and the need and importance of rapidly 
establishing that pericarditis is infectious, if evidence were made available that demonstrates that a simple test, 
such a pericardial fluid pH can be differentiate infectious from non-infectious pericardial effusion, it would make 
a significant impact for clinicians practicing in environments where access to laboratory tests is limited. 
PH has been used for diagnostic purposes in pleural effusions for decades. Several studies have demonstrated a 
correlation between PH and infectious causes at a PH cut off 7.20 and 7.30, irrespective of the serum pH (35) 
(38) and pleural pH has been validated and recommended for use to evaluate pleural fluid.(37). However, the 
pathophysiology of low pH in pleural fluid and other serosa cavities is poorly understood. Existing theories 
suggest that it may be that the pH drop is due to increased production of carbon dioxide (CO2) by leucocytes and 
microbes following glucose metabolism, or by reduced diffusion of CO2, hydrogen ions and glucose across a 
diseased membrane. (47) 
 
Due to the need for a simple straightforward cheap and relatively accurate diagnostic test of infectious pericarditis 
and the potential for pericardial pH to do so, we performed a study to assess the utility of pH in differentiating 
infectious and non-infectious causes of pericardial effusions. We hypothesized that pericardial fluid pH below a 
value of 7.35(which is the cut off used by NHLS for acidic PH) would be able accurately distinguish infectious 
pericarditis (tuberculous and bacterial) from normal pericardial fluid and non-infectious (malignant, idiopathic 
and other inflammatory) 





2.1.1 Design and Methods 
 
Consecutive patients who were 18 years and above referred to Groote Schuur Hospital between the 1st February 
2016 and 31st May2018 with moderate and large effusions for percutaneous or surgical removal of pericardial 
fluid were recruited to participate in the study. The study was approved by the Human Research Ethics Committee 
of the University of Cape Town (HREC/REF: 475/2015 and all participants signed informed consent. All 
participants underwent pericardiocentesis which was performed under aseptic conditions and local anesthetic by a 
qualified physician under echocardiographic or fluoroscopic guidance. The full protocol is given in Appendix D. 
 
The primary study objectives were to: 
 
1. determine if the pericardial pH could accurately differentiate infectious from normal fluid amongst 
patients who referred for diagnostic and/or therapeutic pericardiocentesis; and 
2. to determine the ideal pH cut off between infectious and non-infectious pericardial effusion. 
 
The secondary objective of the study was to assess the ability of pericardial fluid pH to increase the diagnostic 




2.1.2 Research procedures and data collection methods 
 
Once patient signed consent to participate they were then taken to the catheterization laboratory where, under 
aseptic conditions and local anaesthesia, a pericardiocentesis was performed percutaneously to obtain at least  
50ml of pericardial fluid following set standard protocols.(53) The sample obtained was divided into five smaller 
samples. One sample of 10ml was put into a mycobacteria growth indicator tube liquid culture for TB culture; 
another sample of 5 mls was drawn into a heparinized bottle for pH measurement; another sample of 5 mls was 
put into a heparinized bottle for cell count and microscopy for ZN and gram stain; another sample in purple top 
for gene expert for TB; and the final sample of 10mls was drawn in a standard blood culture bottle to culture other 





bacteria. All these samples were delivered to the NHLS laboratory immediately, to allow for timely analysis 
(within an hour) particularly for the pH sample which was delivered on ice to avoid delays. The NHLS laboratory 
was able to receive the samples at any time of the day. 
 
We also obtained pericardial samples from the cardiothoracic surgery unit from patients undergoing cardiac 
surgery during the period of the study with informed consent from the patients 
It was ensured that those involved in pH measurement were blinded to the results for the reference standard and 
those evaluating the reference standard were blinded to pH results and this was done to minimize bias as a 
requirement by standard guidelines of diagnostic studies. 
 
2.1.3 Procedure for sampling and measurement for pH 
Pericardial fluid samples for pH measurement were drawn into a heparinized bottle, as studies have shown no 
effect of pH when heparinized bottles are used.(54) A sample on ice was sent to a chemistry laboratory for the pH 
to be measured within one hour to avoid delays. In an experiment at the NHLS laboratory in preparation for the 
study (as shown in the Appendix) it was demonstrated that pH measurement using pH strips   is affected by the 
concentration of protein in the fluid as these depend on protein dyes and for this reason, this  was not used in this 
study. 
 
2.1.4 Operational Definitions: 
These have been summarized in table 1a in appendix B 
 
2.1.5 Data Management 
All demographic, clinical, blood, pericardial fluid, ECG and imaging data was entered into a CRF and later 
entered into the Redcap database on a daily basis by the study lead investigator (BK), and it was backed up on an 
external drive. Any incomplete data was quickly obtained and entered promptly. This data was then exported to 
STATA version 13.0 software for analysis. 





2.1.6 Statistical considerations and data analysis plan 
 
The objective we used was to determine the accuracy of pericardial fluid pH as a test to differentiate infectious 
versus non-infectious pericardial effusions. Using this objective, using a sensitivity of 70%,  we needed to recruit 
149 subjects for a 95% confidence interval and power of 80%. 
Continuous variables were summarized using mean (SD) for normally distributed continuous variables, median 
(interquartile range-IQR) for non-normally distributed continuous variables while categorical variables were 
expressed as frequencies and percentages. Differences in median pH across groups were analyzed using Kruskal- 
Wallis test for differences in medians. Correlation between pH and specified variables was tested using Pearson 
correlation coefficient. 
Diagnostic accuracy was derived using cultures inclusive of TB culture and other infective organisms and/or gene 
expert for TB, and /or microscopy (with various stains) as a reference standard. 
 
 
For primary objective 1: We determined the median and interquartile range (IQR) pH in the infectious pericardial 
effusions and non-infectious pericardial effusions using Kruskal-Wallis test to assess for differences in the 
medians. We then used the pH cut off of 7.35, to determine the sensitivity, specificity, positive productive value, 
negative productive value, negative and positive likelihood ratios for each of the index tests, and pericardial pH 
measured by blood gas analyzer. 
 
For primary objective 2: Using the AUC, we determined the ideal cut off of median pH for infectious pericardial 
effusions and non-infectious pericardial effusions. 
For secondary objective 1: We determined the sensitivity, specificity, negative predictive value, positive 
predictive value, and negative and positive likelihood ratios of pericardial pH used with ADA, in diagnosing 





Infectious pericarditis due to TB. We also used ROC to compare the AUC for pH alone, and pH used with ADA 
in differentiating infectious and non-infectious pericardial effusions. 
2.1.7 RESULTS: 
 
The study flow chart is given in Figure 2. 200 patients were screened, 60 patients were excluded because their 
effusions were not amenable to percutaneous pericardiocentesis and or had incomplete data for analysis. 
140 participants met the criteria for inclusion in this substudy, the mean age was 46.4 years, 33.6% were HIV 
positive, 24.3% were hypertensive and 70 of these participants were from the surgical cohort. Among these 
participants 21.4% had a known TB diagnosis on appropriate treatment. 
 
Of the 140 participants, 63(45%) were found to have infectious pericardial effusions and majority of these 61.9%) 
had definite infection as described by our reference standard. Table 1 outlines the basic clinical characteristics, 
important significance difference between the two groups included systolic blood pressure, mean pulse rate, 
venous pressure, HIV, HTN and TB status. 
 
Table 2 outlines the basic clinical and echocardiographic characteristics between the two groups and significant 
differences between the two groups including peripheral oedema, size of effusion and features of tamponade. 
 
Tables 3 and 4 outline the X-ray and laboratory findings between the two groups with significant difference found 
in effusion characteristics, LDH, TB microscopy, lymphocyte predominance culture, renal function ,serum 
electrolytes, cholesterol and glucose. 
 
2.1.8 Diagnostic utility of pericardial PH in infectious pericardial effusions: 
 
We found the median (IQR) pH was 7.30 (7.20-7.30) for definite infection, 7.30 (7.30-7.35) for probable infection 
and 7.50 (7.40-7.55) for non-infectious effusions and these were statistically different (p <0.05). The prevalence 
of  infection was 27.1% and that for definite infection was 33% (Table 5 and 6). At pH cut off <7.35, the 
likelihood of detecting a positive result among the truly confirmed positives was 89.5(95% CI: 75%.5-97.1%) 





and the likelihood of detecting a negative result among the truly confirmed negatives was 72.5% (95% CI: 62.8%- 
80.9%). 
Using the receiver operator curve (ROC) (Figure 3 and Table 7), the ideal cut off for pH that would give maximum 
sensitivity and specificity was ≤7.30 and the maximum sensitivity and specificity at optimum cut off are 86.8% 
(95% CI:71.9 - 95.6) and 79.4% (70.3 - 86.8). The area under the curve at this cut-off point is 0.86(95% CI 0.79 
to 0.9), p<0.001. 
2.1.9 Assessing whether addition of ADA to PH increases the sensitivity and specificity with positive culture as 
reference standard 
There was no significant difference in sensitivity between a combination of ADA (>=35) and PH (<7.35) and PH 
(<7.35) alone, p=0.063 (Table 8). Addition of ADA appeared to lower sensitivity (77.1% versus 89.5%). 
However, there was a statistically significant difference in specificities with a combination of ADA (>=35) and 
PH (<7.35) compared to PH (<7.35) alone (p=0.002). Addition of ADA to PH increased specificity by 7.5% 




There were 3 main findings of this study. The first important finding was that pericardial pH is an accurate and 
simple test to differentiate between infectious (definite and probable) and non-infectious causes of pericardial 
effusion. Using a conventional cut-off for acidic pH of 7.35 we found that this value had a sensitivity of 89.5%, a 
specificity of 72.5% and an area under the curve (AUC) value of 0.81. When we used a definition of infectious 
pericarditis that included only samples with a confirmed bacteriological diagnosis (confirmed), the sensitivity of 
89.5%, specificity of 97.4% and area under the curve value 0.93 for a pH of 7.35 improved significantly. 





The second major finding of this study was that the ideal pH cut value to differentiate between infectious (definite 
and probable) and non-infectious causes of pericardial effusions was 7.30. Using Receiver Operating Curve 
(ROC), analysis we determined that a pH of 7.30 worked optimally with a sensitivity of 86.8% , a specificity of 
79.4%, area under the curve(AUC) value of 0.86 and a p value of 0.001. Interestingly this cut off correlates 
closely with the value which is used to differentiate infectious causes of pleural effusions from non-infections 
pleural effusions. (35) (37) 
The 3rd major finding of this study was that the addition of ADA (cut off >35IU) to pericardial fluid pH to 
differentiate between infectious and non-infectious causes of pericardial effusions did not increase the diagnostic 
accuracy. This was surprising given that ADA used alone at a cut off of 35IU, has a sensitivity of 95.7% and a 
specificity of 84.0% for the diagnosis of pericardial fluid TB.(55) This could be because the study was not 
powered enough for this objective. From this data, adding ADA with cut off of >35IU to acidic PH (<7.35) we 
determined an increase in specificity by 7.5% and a decrease in sensitivity by 12.4% although this was not 
statistically significant. 
 
To our knowledge use of pH as a guide to diagnosing infectious effusive pericarditis has not been well utilized  in 
pericardial disease, most likely because its value was not studied before. This study therefore is novel and the first 
of its kind, with largest sample size to date, to demonstrate utility of pericardial fluid PH to identify infectious 
pericardial effusions with a fair degree of confidence. Furthermore, where blood gas analyzers are available, 
preforming pericardial pH is quick and simple allowing early initiation of appropriate and timely management of 
patients with pericardial effusions. 
 
The limitation of this study is  
that we were not able to recruit more patients into the study to further increase the power because some of the 
patients opted not to participate in the study as we initially aimed to recruit 200 patients. We were also affected 
by the number of participants that had incomplete data as they were excluded from analysis, but this was 
necessary to have clean data to answer the research question. 





2.3 CONCLUSION AND RECOMMENDATION: 
 
In conclusion, this study has demonstrated that pericardial PH is a test with diagnostic utility in patients with 
effusive pericarditis. A pH below 7.35 is able to differentiate between infectious and non-infectious pericardial 
effusions with a sensitivity of 89.5% and a specificity of 72.5%. Using the ROC-Curve analysis we have been 
able to demonstrate that a pH of 7.30 offers the best cut off value to differentiate between infectious and non-
infectious causes of pericardial effusions. We have also demonstrated that while pericardial ADA remains a good 
test for the diagnosis of pericardial TB, it does not add to pericardial pH for the purpose of distinguishing 
infectious from non-infectious pericarditis. 
Given the findings of this study we recommend that pericardial pH, which is a simple test, should  be adopted 
in the evaluation of patients with pericardial effusions in order to rapidly and easily recognize those effusions 
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2.5.1 Appendix A: figures and tables for chapter 1 
           




et al (2) 
(n=231) 
1977-83 
























Idiopathic 1999(86.0%) 78(78.0% 377(83.2%) 32(13.7%) 3(2.0%) 
Specific etiology 32(14.0%) 22(22.0%) 76(16.8%) 201(86.3%) 148(98.0%) 
Neoplastic 13(5.6%) 7(7.0%) 23(5.1%) 22(9.4%) 12(7.9%) 
Tuberculosis 9(3.9%) 4(4.0%) 17(3.8%) 161(69.5%) 124(82.1%) 
Autoimmune 4(1.7%) 3(3.0%) 33(7.3%) 12(5.2%) 1(0.66%) 
Purulent 2(0.9%) 1(1.0%) 3(0.7%) 5(2.1%) 6(4.0%) 
 
           Table 2:Summary of studies on pH in pleural fluid 
 
Author Year Study design Ph. cutoff Statistics 
Light et al 1973 
Crossectional, 
diagnostic <7.20 P<0.05 








Houston et al 1987 Descriptive <7.20 - 
J E Heffner et al 1995 
Prospective, 
diagnostic 
<7.29 AUC (92) 




Ferreiro et al 2014 Descriptive <7.20 - 






          Table 3:Summary of studies on pH in pericardial fluid 
 
Author Year Study design Ph. cutoff Statistics 
Laforcade et 
al,(n=48) 
2005 Animal, descriptive 
study 
<7.80 in neoplastic Neoplastic vs 
idiopathic 
Fine et al (n=37) 2003 Animal, descriptive 
study 
No difference Neoplastic vs 
idiopathic 
King et al (n=13) 1983 Crossectional, 
diagnostic 
<7.08 Infectious vs non- 
infectious 
Ekim et al (n=15) 2014 Crossectional, 
diagnostic 
≤7.01 Infectious vs non- 
infectious 





2.5.2: Appendix B figures and tables for chapter 2 (manuscript) 
 
Table1a: Table showing the operational definitions for the study in Chapter 2 
 
 
Definite infection: 1) ) a pericardial effusion with confirmed tuberculous or bacterial 
etiology confirmed by pericardial fluid culture and/or gene Xpert for 
TB(Mayosi et al 2005) 
 
2 a neutrophil predominant exudative effusion with a positive  
pericardial fluid or blood culture for a bacteria known to cause purulent 
pericarditis ( Mayosi et al,2005) 
Probable infection a pericardial effusion which meets alternative criteria for tuberculosis 
etiology (Mayosi et al., 2005) including lymphocyte predominant 
exudate with significantly raised ADA (>40IU) / Interferon gamma, or 
Tygerberg Index >6. (Mayosi et al 05); A neutrophil predominant 
exudative pericardial effusion without positive cultures. 
Non- infectious pericardial effusion This will be a pericardial effusion which does not meet the above 
criteria for definite or probable infectious pericarditis. 
Acidic PH This will be defined as pericardial fluid pH less than 7.35 according to 
the reference standards of the National  Health  Laboratory 
Services.(57) 
Moderate-severe pericardial effusions Effusions of more than 1cm in diastole on echocardiogram that can be 
safely tapped percutaneously. 





























Age in years, 
mean (SD) 
46.4 (16) 41.8 (15.5) 40.6 (12.1) 49.8 (16.6) 56.2 (12.5) <0.01*** 
TB, n (%) 30 (21.4) 20 (51.3) 8 (33.3) 2 (2.9) 0 <0.01** 
HIV, n (%) 47 (33.6) 26 (66.7) 17 (70.8) 4 (5.9) 0 <0.01 ** 
















77 (70-84) 70 (67-84) 75 (66-89) 78 (70-82) 79 (77-84) 0.18* 
Pulse rate, 
median (IQR) 















36.6 (36-37.1) 0.05* 
































Edema, n (%) 17 (12.1) 7 (18) 5 (20.8) 2 (2.9) 3 (33.3) <0.01 ** 
Rate, median 
(IQR) 













62 (57.4-73) 69 (65.7- 
84.8) 
74.5 (65-78.4 <0.01* 
* Kwalis test for comparison of medians 
** Fishers excact test 
*** ANOVA 




















Peripheral Oedema, n (%) 16 (11.4) 7 (18.0) 4 (16.7) 2 (2.9) 0.012 
Ascites, n (%) 8 (5.7) 3 (7.7) 1 (4.2) 2 (2.9) 0.553 
Impaired LV function, n 
(%) 
8 (5.7) 2 (5.1) 1 (4.2) 5 (7.4) 1.000 
Size of effusion, n (%)     <0.001 
Small 48 (34.3) 0 1 (4.2) 47 (69.1)  
Moderate 48 (34.3) 16 (41.0) 13 (54.2) 17 (25.0)  
Large 44 (31.4) 23 (59.0) 10 (41.7) 4 (5.9)  
Tamponade on echo, n (%) 22 (15.7) 12 (30.8) 6 (25.0) 3 (4.4) <0.001 
Swinging heart 12/22 (54.6) 6/12(50.0) 4/6 (66.7) 1/3 (33.3) 0.461 
RA/RV collapse, n (%) 21/22 (95.5) 11/12 (91.7) 6/6 (100.0) 3/3 (100.0) 1.00 
respiratory flow, n (%) 22/22 (100.0) 12/12 (100.0) 6/6 (100.0) 3/3 (100.0) N/A 
Dilated IVC, n (%) 4/22 (18.2) 3/12 (25.0) 0(0.0) 1/3 (33.3) 0.416 
 All comparisons are made using fishers exact test 

























Rhythm, n (%)       
Sinus Tachycardia 56 (40.0) 26 (66.7) 19 (79.2) 5 (7.4) 6 (66.7) <0.01* 
1st degree heart block 1 (0.7) 0 0 1 (1.5) 0  
Normal 82 (58.6) 12 (30.8) 5 (20.8) 62 (91.2) 3 (33.3)  
PR Segment depression, n (%) 4 (2.9) 1 (2.6) 2 (8.3) 0 1 (11.1) 0.05* 
ST Elevation, n (%) 3 (2.2) 2 (5.3) 0 0 1 (11.1) 0.04* 
Globular heart, n (%) 79 (56.4) 39 (100) 23 (95.8) 9 (13.2) 8 (88.9) <0.01* 
Infiltrates, n (%) 44 (31.4) 26 (66.7) 10 (41.7) 5 (7.4) 3 (33.3) <0.01* 
Effusions, n (%) 40 (28.8) 24 (63.2) 6 (25.0) 4 (5.9) 6 (66.7) <0.01* 
Normal, n (%) 59 (42.5) 4 (10.5) 1 (4.2) 53 (77.9) 1 (11.1) <0.01* 
Effusion characteristics, n (%)       
Blood stained 10 (7.1) 2 (5.1) 4 (16.7) 1 (1.5) 3 (33.3) <0.01* 
Serous 62 (44.3) 1 (2.6) 1 (4.2) 60 (88.2) 0  
Serosanguinous 67 (47.9) 35 (89.7) 19 (79.2) 7 (10.3) 6 (66.7)  
Pus 1 (0.7) 1 (2.6) 0 0 0  
LDH, median (IQR) 731.5 (521- 834.5 (605- 777 (534- 257 (168- 854.5 <0.01** 
 1235) 1996) 1127) 458.8) (560.5-  
     1329.5)  
pH, median (IQR) 7.4 (7.3- 7.3 (7.2-7.3) 7.3 (7.3- 7.5 (7.4- 7.2 (7.2-7.3) <0.01** 
 7.5)  7.35) 7.55)   
ADA, median (IQR) 46.2 (31- 54.5 (41- 45 (35-52) 16 (13.8- 35.6 (9-40) <0.01** 
 62.2) 81.2)  19)   
*Fishers exact test 
** Kwalis test for medians 





        Table 4: Table showing laboratory characteristics for patients with moderate to large pericardial 
effusions 
 










predominant, n (%) 
59 (42.1) 28 (71.8) 16 (66.7) 7 (10.3) 8 (88.9) 
TB microscopy result, 
n (%) 
1/81 (1.2) 1/38 (2.6) 0 0 0 
TB culture result, n 
(%) 
17/80 (21.3) 17/38 (44.7) 0 0 0 
Gene expert, n (%) 17/82 (20.7) 16/38 (42.1) 0 0 1/9 (11.1) 
Potassium, median 
(IQR) 
4.1 (3.7 – 4.4) 3.8 (3.4 – 4.2) 4.0 (3.7 – 4.4) 4.15 (3.9 – 4.5) 4.1 (3.5 – 4.9) 
Lactate, median (IQR) 3.1 (1.3 – 5.65) 6.5 (4.8 – 10.8) 4.4 (3.35 – 5.1) 1.35 (1.0 – 1.85) 8.6 (5.8 – 11.2) 
Glucose, median (IQR) 5.15 (3.8 – 5.9) 3.3 (1.6 – 4.4) 4.75 (4.2 – 5.25) 5.7 (5.25 – 6.5) 4.1 (3.0 – 5.8) 
Cholesterol, median 
(IQR) 
1.6 (0.9 – 2.1) 1.8 (1.6 – 2.5) 2.1 (1.8 – 2.3) 0.9 (0.6 – 1.5) 2.9 (1.9 – 3.6) 
Haemoglobin, median 
(IQR) 
10.65 (9.4 – 
12.55) 
10.3 (8.8 – 
11.0) 
9.8 (8.75 – 11.6) 11.5 (9.75 – 13.8) 11.5 (10.7 – 12.9) 
Platelet count, median 
(IQR) 
292 (222 – 
405) 
333 (253 – 
496) 
364 (217 – 468) 258 (204 – 344) 325 (208 – 330) 
WBC count, median 
(IQR) 
7.4 (5.8 – 11.0) 7.1 (5.3 – 10.0) 6.8 (5.0 – 11.3) 7.9 (6.3 – 11.3) 10.9 (9.8 – 14.7) 
Creatinine, median 
(IQR) 
71 (55.9 – 
88.0) 
61 (48 – 81) 69.5 (53 – 75.5) 78 (62.5 – 96.5) 73 (66 – 163) 
Urea, median (IQR) 4.8 (3.9 – 7.3) 4.7 (3.6 – 7.0) 4.1 (3.5 – 5.1) 5.3 (3.9 – 7.4) 9.3 (5.2 – 11.5) 
Blood culture result 
+ve, n (%) 
4/13 (30.8) 4/8 (50.0) 0 0 0 
HIV positive, n (%) 47 (33.6) 24 (61.5) 17 (70.8) 5 (7.4) 1 (11.1) 
Sputum gene Xpert 
+ve, n (%) 
5/26 (19.2) 5/10 (50.0) 0 0 0 





Table 5: Sensitivity, specificity, negative predictive value, positive predictive value, negative and positive likelihood ratios using a 
priori acidic PH cut- off of 7.35 in pericardial fluid. 
 
 
 Acidic pH cut-off of 7.35. GS Reference (95% CI) 
Overall N=140 





LR (positive) 3.3(2.3-4.6) 
LR (negative) 0.2(0.1-0.4) 
AUC 0.81(0.74-0.88) 
 
The reference standard (GS) was any positive of blood culture, genexpert, tbmicroscopy, tbculture, sputum 
genexpert 
 
 Table 6: Diagnostic accuracy of pericardial PH determination on pericardial effusions eligible for pericardiocentesis as a test to 
differentiate between definite infectious and non-infectious pericardial effusions using a cut off of 7.35 
 
 
 Pericardial PH 
Overall N=116 (infect vs. non-infect) 
Prevalence, n (%),95% CI 38(33.0%), (24.0-42.2) 
Sensitivity (95% CI) 89.5%(75.5-97.1) 
Specificity (95% CI) 97.4%(91.0-99.7) 
PPV95% CI 94.4%(81.3-99.3) 
NPV95% CI 95.0%(87.7) 
LR (positive) 95% CI 34.9(8.9-137.7) 
LR (negative) 95% CI 0.1(0.0-0.3) 
AUC95% CI 0.93 (0.88-0.99) 





             Table 7:Ideal Ph cut off using receiver operator curve (ROC) 
 
 Acidic pH with GS Reference (95% CI) 
Overall N=140 
optimal cut off point ≤7.30 
Sensitivity 86.8% (71.9 - 95.6) 
Specificity 79.4% (70.3 - 86.8) 
AUC (p value) 0.86 (0.79 to 0.9) 
Significance level P (Area=0.5) p<0.001 




            Table 8: Diagnostic accuracy of Pericardial PH used in sequence with ADA in TB pericarditis 
 







LR (positive) 4.1(2.6-6.3) 
LR (negative) 0.3(0.2-0.5) 
AUC 0.79(0.71-0.87) 
























Pericardial fluid and blood 
sent to Chem path for pH, 
glucose and ADA 
measurement 
 Pericardial fluid and blood 
sent to microbiology for 
culture, gene Xpert and 
microscopy` 
   
 
  
   
Confirmed infectious; 
TB, bacterial cultures, 
gene Xpert, microscopy 
and other sites 
Non-infectious; 
Malignancy, heart failure, 






Lymphocyte and neutrophil 








200 Patients ≥18 years 
with large pericardial 
effusions in cardiology 
or cardiothoracic units 
Pregnancy test (female) 
medical history, clinical 
exam, CXR, EKG, Echo 













Sensitivity against False positive rate 
 
95% CI of sensitivity and False positive rate 
Ideal cut off-point 
 
The optimum Ph cutoff was ≤0.730. The sentivity and specificity at this optimal cutoff was 86.8 And 79.4 
respectively. The area under the ROC curve at this optimum cutoff was 0.858(p<0.01). This means that at PH 
cutoff of ≤0.730, the Area under the ROC curve is significantly different from 0.5, Hence there is evidence that the 
laboratory test at this cutoff does has ability to distinguish between the two groups(positive /negative) ie the 
discriminating power or the ability of the Ph at this cutoff to categorically classify patients as true positives or true 
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ADA Adenosine Deaminase. 
AUC Area under the curve 




MTB Mycobacterium Tuberculosis 
NHLS National Health Laboratory Service 
NLR Negative likelihood ratios 
PET-CT Positron emission tomography combined with computed tomography 
PF Pericardial fluid 
PLR Positive likelihood ratios 
RIF Rifampicin 
TBP Tuberculous pericarditis. 
TB Tuberculosis 
UIFNγ Un-stimulated interferon gamma 







Infectious pericardial effusion: This was an effusion drained from the pericardial space of a patient, where the 
presence of an infective organism was identified by TB and other bacteria culture and/or gene Xpert for TB, 
and/or positive microscopy (with various stains) on pericardial fluid or from other sites according to another 
clinician’s discretion. 
 
Non-infectious pericardial effusion: This was an effusion drained from the pericardial space of a patient where 
the presence of an infectious organism has not been identified on TB and bacteria culture and /or gene Xpert for 
TB, and /or positive microscopy (with various stains) on pericardial fluid or on other sites according to another 
clinician’s discretion. 
 
Probable infectious pericardial effusion : This was a pericardial effusion which will have a significantly raised 
ADA (>40IU) /or lymphocytic or neutrophilic predominant, or pericardial effusions that were drained from 
pericardial space of patients with positive IMPI clinical prediction score, and of patients with positive IMPI 
clinical score with lymphocyte or neutrophil predominant pericardial fluid. 
 
Acidic pH: This was defined as pericardial fluid pH less than 7.35 according to the reference standards of the 
National Health Laboratory Services.(57) 
Moderate to severe pericardial effusions: Effusions of more than 1cm in diastole on echocardiogram that can 
be safely tapped percutaneously. 





PURPOSE OF THE STUDY 
 
The overall purpose of this study was to improve the diagnosis of infectious pericarditis by introducing a simpler 
and much quicker method of identifying infectious pericardial effusions during pericardiocentesis. This study was 
to determine the diagnostic accuracy of pH estimation in the diagnosis of infectious pericarditis in patients with 
pericardial effusions eligible for pericardiocentesis (effusions of more than 1cm on echocardiogram in diastole) 
presenting to Groote Schuur Hospital. The utility of such a simple test would simplify diagnosis and positively 






Using the blood gas analyzer as the index test, pH in the acidic range (i.e. less than 7.35) would signify an 
infectious cause of a pericardial effusion in patients with moderate to large pericardial effusions. The reference 
standards were MGIT (mycobacteria growth indicator tube) culture for TB, gene Xpert for TB, routine blood 






1. To determine the diagnostic accuracy of pericardial pH determination on pericardial effusions eligible 
for pericardiocentesis as a test to differentiate between infectious and non-infectious pericardial 
effusions 




1. To describe the diagnostic accuracy of pericardial fluid pH determination added to ADA in the 
diagnosis of infectious effusions due to TB. 








1. Median pH and difference between median pH of infectious pericardial effusions as compared to non- 
infectious pericardial effusions. 
2. Median pericardial pH of effusions due to TB as compared to median pericardial pH of effusions due 
to other bacterial organisms. 
3. Sensitivity, specificity, negative predictive value, positive predictive value, negative and positive 
likelihood ratios using acidic pH cutoff of 7.35. 
4. Ideal pH cut off differentiating infectious from non-infectious pericardial effusions using Receiver 





1. Sensitivity, specificity, negative predictive value, positive predictive value, negative and positive  
likelihood ratios of pH used in sequence with ADA in diagnosing infectious effusions due to TB. 







Background: Pericardial disease is known to be a contributor to morbidity and mortality worldwide. In sub- 
Saharan Africa as compared to the western world, infectious causes of pericardial disease are more common. 
Diagnosis of infectious pericardial disease has been challenging in our setting despite improvement of treatment 
modalities. The diagnostic utility of pH in pericardial fluid is unknown, yet this concept is well studied in pleural 
fluid. This study will evaluate the diagnostic utility of pH in infectious compared to non-infectious pericardial 
effusions. 
 
Methods: Effective from February 2016 through May 2018, 165 consecutive patients with pericardial effusions 
eligible for pericardiocentesis were enrolled at a single Centre in Cape Town, South Africa but 25 were excluded 
from analysis due to incomplete data. Mycobacterium tuberculosis culture and/or gene Xpert for TB and/or 
bacteria culture and/or microscopy served as the reference standard for definite infectious pericardial effusions. 
Sensitivity, specificity, positive and negative predictive values, negative and positive likelihood ratios for pH cut 
off of 7.35 will be used and Receiver operating characteristic curve analysis will be used for selection pH ideal 
cut off. 
 
Impact: This study was to evaluate the diagnostic utility of pH with the aim of introducing a simpler and quicker 
method of improving diagnosis of infectious pericardial effusions during pericardiocentesis. 







Global burden of pericardial disease 
 
Pericardial disease remains an important cause of mortality and morbidity in the world (4). 
 
Pericarditis makes up about 5% of admissions in accident and emergency units in the developed world.(5) The 
etiology of pericardial disease in developed countries has been found to be mainly idiopathic in over 89% of 
patients, with the remainder being due to infections and malignancy(6). A study done in Western Europe revealed 
5% of the patients to have infectious pericarditis, which is comparable to data from a study by Imazio et al in 
Western Europe where 20% of cases were due to infectious pericarditis.(7) Over the years the incidence and 
prevalence of pericarditis has been difficult to measure even in developed settings, but subclinical pericarditis has 
been found in 1% of autopsies. (8) 
 
There is a growing burden of pericarditis in Africa and most especially in the sub-Saharan Africa. This is mainly 
due to the huge burden of HIV/AIDS which predisposes patients to TB in various organs/sites including the 
pericardium i.e. TB pericarditis, and other opportunistic infections.(9) In developing countries infectious 
pericardial effusions are more prevalent among patients with pericardial disease than idiopathic causes, as in the 
case of the developed world. A study done by Reuter et al (10) in a large academic hospital in South Africa 
revealed that 71.6% of the effusions were of an infectious cause. In another study done by Pandie et al, 86.1% of 
the patients at another large academic hospital in South Africa had infectious pericarditis.(11) A series of these 
published studies, as described above are in Table 1 highlighting selected papers reflecting the pattern of 
pericardial disease in both developed and developing worlds. 
 
With the high burden of HIV in Sub-Saharan Africa, the number of people presenting with pericardial effusion 
has increased. Of patients presenting with pericardial effusions 67% are HIV positive.(12) 





Table 1: Etiological diagnosis in the published series of acute pericarditis 
 
 Permanyer- 
























Setting Western Europe Western 
Europe 
Western Europe Africa Africa 
Idiopathic 1999(86.0%) 78(78.0% 377(83.2%) 32(13.7%) 3(2.0%) 
Specific 
etiology 
32(14.0%) 22(22.0%) 76(16.8%) 201(86.3%) 148(98.0%) 
Neoplastic 13(5.6%) 7(7.0%) 23(5.1%) 22(9.4%) 12(7.9%) 
Tuberculosis 9(3.9%) 4(4.0%) 17(3.8%) 161(69.5%) 124(82.1%) 
Autoimmune 4(1.7%) 3(3.0%) 33(7.3%) 12(5.2%) 1(0.66%) 
Purulent 2(0.9%) 1(1.0%) 3(0.7%) 5(2.1%) 6(4.0%) 
 
 
Morbidity and mortality of pericardial disease 
 
Patients admitted with acute pericarditis with advancing age and co-infections are over three times and thirteen 
times more likely to suffer in hospital mortality respectively.(13) In the event of HIV infection, patients with 
pericarditis have larger pericardial effusions and more cardiovascular impairment, contributing to greater 
morbidity and later mortality among these patients.(52) A study of 130 patients with infectious pericarditis 
demonstrated a mortality of 67% among patients treated medically, and 24% among those treated surgically. This 
difference in proportion was statistically significant.(58) Overall mortality of patients with non TB purulent 
pericarditis has been found to be 77% and reduced to 55% in those who received appropriate treatment.(15) A  
five year retrospective study of 57 patients in Zimbabwe revealed 100 % mortality among patients with acute 
purulent pericarditis.(16) Another study showed the mortality of purulent pericarditis to be 100% in untreated 
patients in Ohio.(17) Of patients diagnosed with constrictive pericarditis, 60% will die in the next 10 years from 





date of diagnosis.(18) In a study done by Mayosi et al, the overall mortality of patients with TB pericarditis was 
18.05%.(19) 
The presumptive diagnosis of TB pericarditis has been identified as an independent risk factor for mortality, 
especially in HIV positive patients, in whom the risk of mortality is approximately 4.5 times higher [HR 5.35, 
95% CI 1.76-16.25].(21) Patients with pericarditis in the era of HIV have been found to suffer greater morbidity. 
(22) There is increased mortality due to pericarditis among these patients due to cardiac tamponade and 
constriction.(20) However in the recently published IMPI trial, patients with HIV were found to have less 
constriction from TB pericarditis and thus fewer complications from constriction, compared to HIV negative 
population.(19) 
 
Diagnosis of pericarditis 
 
The diagnosis of pericarditis can be made from a medical history, clinical examination, electrocardiogram and 
echocardiogram, although its much more complicated establishing its etiology.(6) The clinical diagnosis is 
reached when a patient has two of the following: typical chest pain, pericardial rub, wide spread ST elevation and 
pericardial effusion. Elevated inflammatory markers such as C-reactive protein and erythrocyte sedimentation 
rate are confirmatory of a diagnosis of pericarditis. (25) Features associated with high risk pericarditis (non-viral 
or non-idiopathic, recurrence, constriction and cardiac tamponade) include: fever >38.0 degrees, sub-acute 
presentation, immunosuppression, trauma, anti-coagulation, myopericarditis, severe pericardial effusion  
(diastolic echo free fluid more than 20mm) and tamponade.(26) 
 
Therapeutic pericardiocentesis is recommended in patients that have symptomatic large (effusions ≥ 2cm on 
echocardiogram in diastole). Pericardial effusions and diagnostic pericardiocentesis is recommended where there 
is a high suspicion of infectious and neoplastic pericardial effusions.(27) Cardiac catheterization and FDG uptake 
with PET-CT have also become very useful in diagnosis of pericardial disease especially in effusive pericarditis 
and pericardial malignancy respectively.(28, 29) 
 
Newer point-of-care diagnostic tests have been introduced. Adenosine Deaminase (ADA) has been used in the 
diagnosis of TB pericarditis (TBP). A Meta-analysis showed pooled sensitivity was 0.96 and specificity was 0.96 
(30). Pandie et al showed that unstimulated interferon gamma (uIFNγ) offers superior accuracy for the diagnosis 
of microbiologically confirmed TBP, compared to the new Xpert MTB/RIF test and the established ADA assay. 
(11) Magnetic resonance and CT have been found to be useful in the diagnosis of pericarditis in the presence of 





constriction and a mass.(31) Pericardial biopsy is useful in diagnosing and determining specific etiology, 
especially in patients who are having recurrent pericarditis (33). 
 
The diagnosis of pericarditis is very challenging, especially infectious pericarditis and TB pericarditis, and this 
has great impact on mobility and mortality (34). The use of simple and affordable tests may simplify and speed  
up the diagnosis of disease, and thus improve the outcome from disease treatment. In the study done by Pandie et 
al, over 87% of pericardial effusions were infectious and the outcome was worse in the non-infectious group.(11) 
A simple test, such as pH to differentiate infectious from non-infectious pericardial effusion, will then be very 
useful as it will simplify and enable timely and appropriate patient management and thus improve the outcome. 
 
Studies done on pH on pleural fluid: lessons learnt 
 
PH has been used in pleural effusions for diagnostic purposes and therefore this study will be useful to asses if  
we can adapt the use of pH in diagnosis of pericardial effusions. Pleural pH less than 7.30 has been found to 
correlate with infectious causes of pleural effusions, irrespective of the serum pH. (35). In a meta-analysis of 
chemistry predictors of complicated pleural effusions, pH was found to be the most effective predictor of 
complicated (infected) pleural effusion, [AUC:0. 92, CI: 0. 90-0.94] (36). PH as a diagnostic tool in pleural 
disease has been validated and recommended for use.(37) Pleural fluid studies have been done where pleural pH 
less than 7.2 was used to signify infectious pleural effusion.(38) 
 
Pleural fluid pH provides more useful information for estimating the likelihood of pleurodesis failure, for which 
continuous likelihood ratios provide more information than binary or multilevel likelihood ratios.(39) pH less 
than 7.2 has been found to predict infectious pleural effusion, and is thus a guide to management of such 
patients.(40) A study done by Light et al showed pH less than 7.2 to signify infectious pleural effusion and 
demonstrated that patients who were treated successfully with antibiotics showed their pH go above 7.2.(42) 
 
Another study demonstrated that pH less than 7.3 and glucose less than 60mg/dl signify infectious pleural 
effusions.(43) A study by Potts et al also revealed pH less than 7.3 signified infectious pleural effusions.(44) 
Ferreiro et al revealed that pH less than 7.2 signifies pleural effusions complicated by infection.(45) In a study by 
Fanjul et al an acidic pH less than 7.0 was found not only to be a predictor of pleural effusions complicated by 
infection, but was also a marker of poor outcome, thus prognostic.(46) Table 2 below illustrates some of the 
studies described above. 





Table 2: pH studies in pleural fluid with their cutoffs from different studies: 
 
Author Year Study design Ph. cutoff Statistics 












Houston et al 1987 Descriptive <7.20 - 
J E Heffner et al 1995 
Prospective, 
diagnostic 
<7.29 AUC (92) 




Ferreiro et al 2014 Descriptive <7.20 - 
 
Mechanism of low pH in pleural fluid and other serosa cavities 
The pathophysiology of low pH in pleural fluid and other serosa cavities is poorly understood. However, existing 
theories suggest that it is due to an increased production of carbondioxide (CO2) by leucocytes and microbes from 
glucose metabolism, and by reduced diffusion of CO2, hydrogen ions and glucose across a diseased 
membrane.(47) 
 
Use of pH in pericardial disease 
The use of pericardial pH as a guide to diagnosis has not been well indicated. Animal studies have had 
contradictory results with the use of pH in pericardial fluid analysis, with some demonstrating a pH lower than 
7.8 in neoplastic pericardial effusion, as opposed to idiopathic pericardial effusions, and others not demonstrating 
a difference in the two categories in dogs (48, 49). However, these studies did not assess the use of pH in 
differentiating between pericardial effusions of infectious and non-infectious etiology. A small study of 13 
surgical patients has shown that pH less than 7.08 is associated with infectious pericardial effusions.(50) Another 
small study done on 15 children with purulent pericardial effusions revealed an average pH of 7.01± 0.06. 
However, these children were culture negative for both pericardial effusions and blood.(51) These studies are 
illustrated in the Table 3 below. 





Table 3: Studies done on pericardial fluid pH 
 
Laforcade et al, 
(n=48) 
2005 Animal, descriptive 
study 
<7.80 in neoplastic Neoplastic vs 
idiopathic 
Fine et al (n=37) 2003 Animal, descriptive 
study 
No difference Neoplastic vs 
idiopathic 
King et al (n=13) 1983 Crossectional, 
diagnostic 
<7.08 Infectious vs non- 
infectious 
Ekim et al (n=15) 2014 Crossectional, 
diagnostic 




Due to the behavior and characteristics of pericardial fluid compared to pleural fluid, Lights’ criteria have not 
been found to show the same applicability in differentiating exudative and trunsudative effusions.(49) 
 
Due to these uncertainties in the use of pH in pericardial disease, we will carry out a study to assess the utility of 
pH in differentiating infectious and non-infectious causes of pericardial effusions. 









This will be a cross sectional diagnostic accuracy study in patients with pericardial effusions selected for 
pericardiocentesis at Groote Schuur Hospital. 












Patients above 18 years who will give informed consent to participate in the study attending Groote Schuur 
Hospital during the study period. 









Using a proportion of 86.1 % found by Pandie et al, and for a confidence interval of 95% and alpha of 5 %, the 
sample size should be 184. (11) The different calculated sample sizes for different confidence intervals are 
illustrated in Table 4 below. 
 
We estimated the sample size using proportions for crossectional studies.(59) 
 
Our assumptions were a population size of over 1 000 000 and a confidence limit as a percentage of 5%. 









Sample size n = [DEFF*Np (1-p)]/ [(d2/Z21-α/2*(N-1) + p*(1-p)] 
 
DEFF=design effect, N= population size, p=hypothesized frequency of outcome factor in population, 
d=confidence limits as percentage of 100, α = size of critical region 
Our target will be to recruit 200 patients for the study, as we aim to have a more than 5% increase in estimated 
sample size to cater for errors in sampling and measurements of outcome. 















Where nse= sample size, Se=sensitivity, Prev= Prevalence, d= precision estimate 
 
We estimated the sample size for our set sensitivity of 70% using the above equation, we will need to recruit 
149 subjects for a 95% confidence interval and power of 80%. 
 
A sample size of 200 was planned but we were only able to collect 165 and 25 were excluded from analysis due 
to incomplete data leaving a total of 140 samples. 
 
 






Recruitment and enrolment 
 
Consenting patients referred to Groote Schuur Hospital cardiology division, with moderate to severe pericardial 
effusions safe for pericardiocentesis (more than 1cm in diastole on echocardiogram), were consecutively recruited 
and enrolled into the study by the lead investigator (BK), starting on 2nd February 2016. We also obtained 
pericardial fluid from patients undergoing cardiac surgery from the cardiothoracic surgeon as part of the normal 
pericardial fluid. These control samples were only drawn from cardiac surgery patients who had given informed 
consent. We obtained 43 samples as controls, and the majority of these effusions were from patients with non- 
diseased pericardium. These were added to our sample size to increase the number of normal effusions. This was 
thought to give the study greater capacity to distinguish between infectious and non-infectious/normal pericardial 
effusions by increasing the ratio of non-infectious to infectious pericardial effusions. 
The patients were examined for blood pressure, weight, height, pulse rate and jugular venous pressure (JVP). 
They had their blood drawn to measure renal function and full blood count, and they had a chest X-ray, a 12-lead 
electrocardiogram and an echocardiogram. 
 
 
Research procedures and data collection methods 
 
Fully consenting patients were recruited into the study with purpose of obtaining the following information: 
Demographic variables: age, sex, weight, height and home address. 
Clinical variables: Pulse rate, Blood pressure, jugular venous pressure (JVP), height in meters and history of 
constitutional symptoms. 
Investigations: electrocardiogram, history of constitutional symptoms, pericardial and serum glucose, cholesterol, 
sodium, potassium and pH levels, HIV status, chest x-ray and echocardiography findings. We also included 
relevant microscopy and culture results. 
All these data will be recorded by the lead investigator and entered into RedCap and subsequently exported to 
STATA for analysis. 





Patients were then be taken to the catheterization laboratory where, under aseptic conditions and local anesthesia, 
a pericardiocentesis was performed percutaneously to obtain at least 50ml of pericardial fluid following set 
standard protocols.(53) 
The sample obtained was divided into five smaller samples. One sample of 10ml was put into a mycobacteria 
growth indicator tube liquid culture for TB culture; another sample of 5 mls was drawn into a heparinized bottle 
for pH measurement; another sample of 5 mls was put into a heparinized bottle for cell count and microscopy for 
ZN and gram stain; another sample in purple top for gene expert for TB; and the final sample of 10mls was drawn 
in a standard blood culture bottle to culture other bacteria. All these samples were delivered to the NHLS 
laboratory immediately, to allow for timely analysis (within an hour) particularly for the pH sample which was 
delivered on ice to avoid delays. The NHLS laboratory was able to receive the samples at any time of the day. 
The study schedule is illustrated in Table 5 below. 
We also obtained pericardial samples from the cardiothoracic surgery unit from patients undergoing cardiac 
surgery during the period of the study with informed consent from patients, as described in the section on 
recruitment and enrolment. 
It was ensured that those involved in pH measurement were blinded from the results for the reference standard. 















Pericardial fluid and blood 
sent to Chem path for pH, 
glucose and ADA 
 Pericardial fluid and blood 
sent to microbiology for 
culture, gene Xpert and 
   
Probable infectious; 
Clinical judgment 
Lymphocyte and neutrophil 
predominant effusions, IMPI 
Non-infectious;  
Malignancy, heart failure, 
renal failure, systemic lupus, 
idiopathic, others 
Confirmed infectious; 
TB, bacterial cultures, 
gene Xpert, microscopy 
and other sites 
Patients ≥18 years  
with large pericardial 
effusions in cardiology 
or cardiothoracic 
Pregnancy test (female) 
medical history, clinical 

















Immediately 2 to 10 days 2 to 4 weeks 
Consent (study) ✓    
Consent 
(Pericardiocentesis) ✓ 
   
Medical History & 
Exam 
✓    
Pericardiocentesis ✓    
Drawing blood ✓    
Chest X-ray  ✓   
EKG  ✓   
Echocardiogram ✓    
pH (blood & 
Pericardial) 








   
Blood culture 
results 
  ✓  
ADA measurement  ✓   
TB culture 
results 





   
Total blood 10mls    
 
 
Procedure for sampling and measurement for pH; 
 
Samples for pH measurement were drawn into a heparinized bottle, as studies have shown no effect of pH when 
heparinized bottles are used.(54) We sent the sample to a chemistry laboratory for the pH to be measured within 
one hour on ice to avoid delays. pH was measured with a blood gas analyzer. pH on fluid has been found to 





remain stable within the first hour at room temperature from a study which disputes the myth that fluid has to be 
collected and kept on ice at zero degrees but we delivered it on ice because it creates a sense of urgency on 
sample processing .(60) We also ensured that the other samples are kept at room temperature and pH measurement 
will be done within one hour of sample collection.(61) We chose to use this method of collection because the 
studies that suggested pH changes at room temperature were small studies, but larger and more recent studies 
showed no significant change in pH at room temperature over an hour, with four measurements done at 15,30,45 
and 60 minutes respectively.(62) In an experiment that we conducted in NHLS laboratory in preparation for our 
study (as shown in the Appendix) we demonstrated that pH measurement using pH strips is affected by the 





Data was entered into a CRF and later entered into the Redcap database on a daily basis by the study lead 
investigator (BK), and it was backed up on an external drive. Any incomplete data was quickly obtained and 





Continuous variables were expressed as mean (SD) while categorical variables were expressed as number and 
group percentages. Differences in pH between groups were analyzed using unpaired Student t test and one-way 
Anova. Correlation between pH and specified variables was quantified using Pearson correlation coefficient. 
 
Diagnostic accuracy was derived using cultures inclusive of TB culture and other infective organisms and/or gene 
expert for TB, and /or microscopy (with various stains) as reference standard. 
For primary objective 1: We determined the mean pH in the infectious pericardial effusions, and mean pH in non- 
infectious pericardial effusions, using the STATA version 11.0. We also determined the median pH of infectious 
and non –infectious pericardial effusions. We then use the pH cut off of 7.35, as stated by NHLS, to determine  
the sensitivity, specificity, positive productive value, negative productive value, negative and positive likelihood 
ratios for each of the index tests, and pericardial pH measured by blood gas analyzer. 





For primary objective 2: Using the AUC, we will determine the ideal cut off of median pH for infectious 
pericardial effusions and non-infectious pericardial effusions and determine AUC. 
For secondary objective 1: We determined the sensitivity, specificity, negative predictive value, positive 
predictive value, and negative and positive likelihood ratios of pericardial pH used with ADA, in diagnosing 
Infectious pericarditis due to TB. We also used ROC to compare the AUC for pH alone, and pH used with ADA 
in differentiating infectious and non-infectious pericardial effusions. 
 
We also proceeded to determine the median pH of pericardial effusions due to TB, and effusions due to other 
bacteria. 




Description of risks and benefits 
 
Eligible patients had percutaneous pericardiocentesis and the risks, which include pain, arrhythmias and 
myocardial puncture, were explained to all participants. The only adverse event was pain which was managed 
promptly with local anaesthetic. 
 
The benefits of the study to the patients were: urgent lifesaving pericardiocentesis, and timely diagnosis, treatment 
and appropriate referrals to alleviate their medical condition. 
Informed consent process 
The principal researcher explained to each patient the study question we were  trying to answer, the importance  
of the study, the benefits and the risks, the exact procedure of percutaneous pericardiocentesis and what would 
happen after their contact with the study team. This was done in English, and a study nurse or/and a translator 
would translate and explain to those patients who did not speak English. Patients who were temporarily 
cognitively impaired were consented through a legally accepted representative or legal guardian. The consenting 
patients were given a form to sign in the presence of a witness. 
 
Privacy and confidentiality 
Participant information was be handled in great confidence. Access to information was limited to the study 
investigators, and in case of presentations or publications no patient identifiers would be displayed. 





Reimbursement for participation 




Emergency care and insurance for research related injuries 
The patients were seen and managed by a team of doctors at Groote Schuur Hospital and thus we minimized the 
risks of injuries and any patients’ injuries were managed in the hospital immediately. 
 
The UCT no fault insurance clause applied to this study as incorporated in the informed consent form. 
 
What happens at the end of the study? 
 
The results from the study were to be published in a reputable journal. 
 
We ensured that patients got appropriate management for the causes of their pericardial disease and timely 
referrals where need is required. 
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 Exudate Transudate 
Fluid/Serum Protein >0.5 <0.5 
Fluid/Serum LDH >0.6 <0.6 
Serum LDH >200IU <200IU 
★LDH; Lactate dehydrogenase 
 




HIV status Positive 
Constitutional symptoms Present 





pH laboratory experiment done by Dr. Brian Kiggundu and Prof. David Marais: 
 
We undertook a table Ph experiment with Prof. Marais today (14th/July/2015) 
 
The aim was to do a quick evaluation of the effect of protein on pH indicator strips and paper strips. 
 
As discussed earlier in the Chem path meeting, pH estimation by pH indicator strips and indicator paper is affected 
by protein and thus errors in pH estimation. 
 
Given the fact that we shall be measuring pH on exudates, which have high protein, we may have these errors. 
We evaluated how well a urine dipstick and pH paper indicator does with a change in protein concentration. 
We measured pH using dipstick and pH Paper indicator at different protein concentration by diluting serum with 
a buffer from a protein concentration of 70g/l to 1.1g/l. We discovered that the pH paper indicator showed much 
higher pH than expected and with dipsticks we got varying pH readings at high protein concentration, but more 
consistent readings at lower protein concentration. 
 
We also found it difficult to read exact pH values, which are in between colors for example 7.5. pH also changed 
with time; it became higher. 
 
Conclusion was that pH indicator strips are affected by protein content in fluid and it is difficult to differentiate 
between pH readings that are in between two colors. However, if we can get strips that have user-friendlier cut 
offs to allow more discrimination between pH values, then we can use the pH strips, since we shall be comparing 
them to the blood gas analyzer. If they are useless at the end of the study, we will draw that conclusion. 
 
We will also ensure that pH is measured immediately. 
 
BUDGET 
Item Cost per Patient Quantity Total 
Pericardial 
determination pH by 





















pH by pH meter R100.00 200 R20, 000.00 
Printing R4.00 250 R9, 000.00 
Total   R59, 000.00 




    
Grand Total   R64, 900.00 
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II: Monograph format. 
 
I: Publication format 
 
The dissertation must include a manuscript in publication-ready format and should be structured as follows: 
 




In this section the student should put the research in medical, social, geographical and economic perspective by providing 
the relevant background, research setting and rationale of the research. This should not be a full literature review, but the 
candidate may need to enlarge on the introduction in the publication-ready manuscript to facilitate a clear motivation of    
how their research contributes to advancing scientific knowledge with particular referance to the research setting. If there  
are aspects of the methodology that merit more detail than was afforded in the submitted paper, a subsection titled 
“methodological aspects” should be included. References quoted in this chapter should appear at the end of the chapter,  
not at the end of the thesis. 
 
1.2 Ethical considerations 
 
In this section the student should discuss how the ethical considerations were addressed and state the relevant HREC 
approval number(s). 
 
Note: The word count for part 1.1 and 1.2 combined should not exceed 2000 words. 
 
1.3 Author guidelines of the Journal for which the paper has been formatted 
 
Unless specially motivated, the journal chosen should allow for at least 2000 words (not more than 5000 words) excluding 
abstract, tables, figures and references. The “Instructions to Authors” of the journal must be appended. The journal     
chosen for publication must be appropriate to the subject matter of the dissertation – the reason for choice should be 
motivated here. The journal must also be listed in the citation index of the Institute for Scientific Information (ISI) or 
accredited by the South African Department of Education: 
(http://www.lib.uct.ac.za/medical/index.php?html=/libs/accredjnls.htm&libid=24) 
 
Chapter 2: Publication-ready manuscript 
 
The study is presented in the form of a manuscript of an article for a named peer reviewed journal, meeting all the 
requirements set out in the “Instructions for Authors” of that journal, including the word count and referencing style. Unless 
specially motivated, the journal chosen should allow for at least 2000 words (not more than 5000 words) excluding    
abstract, tables, figures and references. The “Instructions to Authors” of the journal must be appended. The co-authors 
should be listed in the appropriate order, and each of their contributions to the manuscript stated. The journal chosen for 
publication must be appropriate to the subject matter of the dissertation and listed in the citation index of the Institute for 
Scientific Information (ISI) or accredited by the Department of Education 
(http://www.lib.uct.ac.za/medical/index.php?html=/libs/accredjnls.htm&libid=24); other journals with similar  review 
processes, particularly South African journals may be acceptable if permission is obtained from the PMC Chair after 
appropriate motivation is provided. 
 
Note 1: In this format, the candidate need not have submitted the article for publication, nor is the acceptance of the article 
for publication a requirement for passing the degree. However, the norm is to publish the study with the supervisor(s) as co-
author(s), and candidates are strongly encouraged to submit their manuscript for publication after examination of the minor 
dissertation. 
 
NOTE 2: IF THE RESEARCH IS A FULL SYSTEMATIC REVIEW, THERE IS NO NEED FOR A SEPARATE CHAPTER 1 
– THE REVIEW SHULD BE SUBMITTED AS ONE CHAPTER. 
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II: Published (or accepted for publication) paper format 
 
A manuscript that has already been published or accepted for publication in a journal that is listed in the citation index of   
the Institute for Scientific Information (ISI) or accredited by the Department of Education (other journals with similar review 
processes, particularly South African journals may be acceptable if permission is obtained from the PMC Chair after 
appropriate motivation is provided), may be submitted if the candidate was the first author, the candidate’s  
contribution was completed under supervision during his/her registration for the degree, and the paper is in line 
with the educational aims and scope of research described in the first part of this document. 
 
The dissertation must be submitted in similar format to the publication-ready format – the only differences being: a    
separate literature review is not required; the accepted publication is submitted as a single chapter following the same  
format as described above under “Chapter 2”; and the reviewer comments from the journal should be attached as an 
appendix. When this format is used, the contributions of all the authors must be very clearly stated under a sub-heading in 
the “Acknowledgments and contributions” section in the first part of the thesis. 
 
III: Standard monograph format 
 
Some disciplines and constituent Colleges of the Colleges of Medicine of South Africa require a standard monograph 
presented in a comprehensive and scholarly style to be submitted as part of the examination. The length is typically 16     
000 to 20 000 words in length, but may vary. If the length is not stipulated, the monograph should be 6000 – 16000 words, 
excluding references and tables. 
 
A recommended structure for the body of the dissertation is as follows; 
 
Chapter 1: Introduction and Literature review 
 
(see guidelines above) 
 
Chapter 2: Methods 
 
Material and methods of the study must be fully described and factually presented. 
 
Chapter 3: Results 
Chapter 4: Discussion and conclusions 
 
Appendices (relevant to all formats) 
 
All other relevant supporting documents should be appended, including: 
 
• Questionnaire/data capture instrument(s) 
• Consent forms and related participant information sheets 
• Technical appendices and relevant additional tables not included in the main manuscript. 
 
These should be accompanied by a brief narrative. 
 
• Ethics approval letters (except for a full systematic review) and other relevant permissions 
• Instructions to authors if format I or II is submitted 
• Reviewer comments if format II is submitted 
 
Language and writing 
 
Clear, grammatically correct English is essential. 





Supervisors may assist candidates in developing scientific communication skills but they are not required to do 
detailed editing or correction of spelling, grammar, or style. Training in scientific writing is available at the Health 
sciences Writing Centre. Registrars need to make an appointment via the website: 
http://www.writingcentre.uct.ac.za/about/healthsciences 
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Candidates should refer to Form D4, Guidelines on the Layout and Style of the Dissertation or Thesis. As long as the 
dissertation is readable and internally consistent, any of a number of styles are acceptable. For a publication-ready 
manuscript, references should be formatted according to the instructions to authors for the  journal selected, and   
candidates should use the same style throughout their dissertation. For a monograph format manuscript, the Harvard style 
for referencing is recommended, but not compulsory. For reference management, Refworks or Endnote can be    
downloaded from the ICTS or UCT library website. 
 
Candidates should look at previous examples of Master’s dissertations in the library. Master’s dissertations are available     
in the Health Sciences Library. A search will need to be done to obtain a list of titles and authors. This search can be done 
using search words (e.g. dissertation, health, health sciences, etc.). The librarian can be asked for assistance. Some of 




After 1 year, apply to HREC for continuing approval Form FHS016 (for intervention study) or FHS017 (for record review)   
or submit a study closure form, FHS010, if the study is complete. If registration in MMED III is required for more than one 
year then complete form D2(b) and submit to Post Grad Office when re-registering. 
 
Submission of dissertations 
 
On completion, the dissertation and a Turn-it-in originality report must be submitted to the Faculty Postgraduate Office.    
The candidate should inform the Faculty Officer one month in advance of the intention to submit, using Form D8 (Intention  
to submit) online with PeopleSoft system and should subsequently submit their dissertation using the same system – 
guidelines for this process and the use of Turn-it-in are on the Mmed/Mphil Vula Website and detailed guidelines 
are also available in the UCT student help document: “ Digital  submission  of  a  thesis/dissertation  for 
examination and library access”. This document is available online at 
http://www.uct.ac.za/usr/current_students/postgrad/digital_upload_dissertations_theses.pdf 
 
Supervisors will be requested by the Faculty Postgraduate Officer to submit a letter supporting submission, and clearly 
specifying whether the format of submission, so that the appropriate instructions are sent to the examiners. This letter 
should be supplied by the primary supervisor. If this supervisor is external, the internal supervisor must be kept informed  
at every stage of the process. 
 
Please note: In the event that any of your external examiners request a hard copy of your dissertation/ thesis, you will be 
required to supply this. The Faculty office will inform you should this be necessary. 
 
Specific submission requirements may be set by individual disciplines or constituent Colleges of the CMSA, and registrars 





for June graduation 
2. August 15
th 
for December graduation 
 
Note on fees: To avoid attracting fees, dissertations need to be submitted before the beginning of the first quarter (first 
day of academic year), and before the start of the second semester (mid July) to qualify for a 50% fee rebate. 
 
Examiners 





The full dissertation will be  submitted for examination through the Postgraduate Office to two examiners (nominated by    
the supervisors and HOD) – at least one examiner must be external to UCT. An internal examiner must not be involved in 
the research. 
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It is the supervisors’ responsibility to submit names of three potential examiners (or two examiners who have already  
agreed to examine pending approval of the Post Graduate Office) to the Faculty Officer when the candidate is ready to 
submit. Appointment of examiners from outside South Africa is encouraged. These nominations need to be approved by   
the Deputy Dean: Postgraduate Affairs on behalf of the Faculty Board and submitted to the Faculty Board for ratification    
via a Dean’s Circular. Details required for each examiner are: academic qualifications, postal and/or physical address, 
telephone and fax numbers and e-mail address, and one paragraph description of their standing in the relevant field    
(drawn from their CV if need be). The examiners will be sent a copy of these guidelines as well as a guideline for marking. 
The candidate may not be informed of the identity of the examiners. After the outcome of the minor dissertation has been 




The university has a moral responsibilty to publish all research undertaken when publication is stated as an anticipated 
output. A candidate who fails to submit a manuscript to a journal for publication within 1 year of submission of their thesis, 
must accept that their supervisor(s) are entitled to publish their data on their behalf, with the student as co-author - this 
should be stated in the memorandum of understanding. 
